Maya Katz, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Regents Univ of California UCSF · 276 clinicians in this group
Hospitals listed: 057031 · Marinhealth Medical Center · Sonoma Valley Hospital. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Katz’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A115851 · Current
Licensed to practise in California · since 2011 · expires 2028-06-30 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$35,000
Medicare paid this office $35,000 for 131 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 57 | $14,346 | $161 |
| Long return visit (40+ min) | 56 | $10,224 | $123 |
| Return visit (30+ min) | 15 | $1,674 | $105 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $1,106 | $28 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $887 | $30 |
Who their Medicare patients are
131 Original Medicare patients in 2024. Average age 75 · Under 65 11% · 85 and older 9% · Women 45% · Also on Medicaid 20% · Health risk score 1.74. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 58% · Depression 42% · Diabetes 29% · Dementia 27% · Coronary heart disease 24% · Atrial fibrillation 21% · Chronic kidney disease 18% · COPD 16% · Heart failure 15% · Cancer 14% · Stroke 14%.
The office billed $164,192, Medicare allowed $47,302 and paid $35,000; for 364 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 131 | 364 | 75 | 1.74 | $164,192 | $35,000 |
| 2023 | 194 | 681 | 74 | 1.57 | $299,831 | $65,506 |
| 2022 | 331 | 890 | 74 | 1.56 | $348,195 | $80,583 |
| 2021 | 350 | 994 | 74 | 1.44 | $406,510 | $103,278 |
| 2020 | 125 | 518 | 73 | 1.68 | $329,502 | $45,981 |
| 2019 | 69 | 279 | 72 | 1.72 | $168,112 | $22,456 |
| 2018 | 73 | 223 | 73 | 1.65 | $143,797 | $19,023 |
| 2017 | 83 | 287 | 72 | 1.80 | $179,333 | $26,222 |
| 2016 | 86 | 264 | 71 | 1.56 | $156,425 | $22,440 |
| 2015 | 77 | 300 | 67 | 1.37 | $175,680 | $25,575 |
| 2014 | 95 | 341 | 69 | 1.39 | $195,213 | $28,818 |
| 2013 | 35 | 146 | 68 | 1.67 | $39,860 | $6,115 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 142 | $43,023 | $127 |
| Return visit (30+ min) | 59 | $6,980 | $85 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,622 | $81 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 11 | $1,590 | $43 |
| New patient visit (60+ min) | 12 | $1,518 | $127 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | $1,073 | $28 |
| Muscle electrical test | 19 | $627 | $18 |
2022: 11 services
| Long return visit (40+ min) | 215 | $43,090 | $113 |
| Return visit (30+ min) | 106 | $10,904 | $85 |
| New patient visit (60+ min) | 29 | $4,684 | $162 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 20 | $4,629 | $119 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 14 | $2,282 | $88 |
| New patient visit (45+ min) | 19 | $2,264 | $119 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 34 | $1,505 | $27 |
| Advance care planning, first 30 minutes | 21 | $1,350 | $56 |
| Muscle electrical test | 37 | $1,118 | $17 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | $916 | $42 |
| Short return visit (20+ min) | 13 | $705 | $54 |
2021: 11 services
| Long return visit (40+ min) | 234 | $55,751 | $128 |
| New patient visit (60+ min) | 109 | $17,091 | $157 |
| Return visit (30+ min) | 77 | $9,328 | $88 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 15 | $3,584 | $119 |
| Advance care planning, first 30 minutes | 32 | $2,642 | $70 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 15 | $2,457 | $91 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 48 | $2,042 | $29 |
| Short return visit (20+ min) | 24 | $1,754 | $60 |
| New patient visit (45+ min) | 11 | $1,376 | $125 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | $1,252 | $46 |
| Muscle electrical test | 25 | $694 | $19 |
2020: 7 services
| Long return visit (40+ min) | 100 | $20,001 | $98 |
| Extended office or other outpatient service, first hour | 41 | $5,528 | $108 |
| Advance care planning, first 30 minutes | 34 | $3,864 | $72 |
| Extended patient service without direct patient contact, first hour | 38 | $3,845 | $99 |
| New patient visit (60+ min) | 23 | $3,282 | $143 |
| Return visit (30+ min) | 15 | $1,441 | $69 |
| Muscle electrical test | 11 | $387 | $17 |
2019: 4 services
| Long return visit (40+ min) | 56 | $10,943 | $96 |
| Extended office or other outpatient service, first hour | 16 | $2,198 | $110 |
| Return visit (30+ min) | 17 | $1,421 | $68 |
| Advance care planning, first 30 minutes | 14 | $1,286 | $71 |
2018: 2 services
| Long return visit (40+ min) | 50 | $8,800 | $92 |
| Return visit (30+ min) | 19 | $1,328 | $63 |
2017: 4 services
| Long return visit (40+ min) | 60 | $13,728 | $95 |
| Extended office or other outpatient service, first hour | 15 | $2,840 | $109 |
| Return visit (30+ min) | 13 | $1,055 | $70 |
| Muscle electrical test | 11 | $293 | $17 |
2016: 4 services
| Long return visit (40+ min) | 55 | $9,848 | $94 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 12 | $1,999 | $118 |
| Return visit (30+ min) | 19 | $1,413 | $67 |
| Muscle electrical test | 13 | $314 | $18 |
2015: 5 services
| Long return visit (40+ min) | 41 | $8,443 | $91 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 13 | $2,932 | $133 |
| Return visit (30+ min) | 22 | $1,409 | $52 |
| Long return visit (40+ min) | 11 | $1,010 | $92 |
| Muscle electrical test | 19 | $496 | $18 |
2014: 6 services
| Long return visit (40+ min) | 49 | $9,120 | $93 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 16 | $5,018 | $173 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 18 | $3,186 | $127 |
| Return visit (30+ min) | 36 | $2,742 | $65 |
| New patient visit (60+ min) | 12 | $1,688 | $141 |
| Muscle electrical test | 33 | $822 | $18 |
2013: 2 services
| Return visit (30+ min) | 16 | $1,086 | $68 |
| Muscle electrical test | 13 | $282 | $18 |
Medicaid work
$488 in 2023
Medicaid paid $488 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $488 |
| 2023 | 12 | 1 | 12 | $488 |
Drugs they prescribed that Part D paid
$457,441
Pharmacies billed $457,441 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,094 generic and fewer than 11 brand-name prescriptions · $457,441 in drug cost · 29 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 95 | $267,473 | $2,816 |
| Inbrija | None | 17 | $67,108 | $3,948 |
| Myrbetriq | None | 42 | $28,666 | $683 |
| Carbidopa-Levodopa Er | None | 84 | $13,132 | $156 |
| Carbidopa-Levodopa | None | 216 | $7,695 | $36 |
See all 29 drugs
| Rytary | Parkinson's | 95 | $267,473 | $2,816 |
| Inbrija | None | 17 | $67,108 | $3,948 |
| Myrbetriq | None | 42 | $28,666 | $683 |
| Carbidopa-Levodopa Er | None | 84 | $13,132 | $156 |
| Carbidopa-Levodopa | None | 216 | $7,695 | $36 |
| Carbidopa | None | 20 | $5,298 | $265 |
| Amantadine | None | 46 | $4,111 | $89 |
| Rivastigmine | None | 16 | $2,830 | $177 |
| Celecoxib | None | 51 | $2,118 | $42 |
| Midodrine | None | 18 | $1,537 | $85 |
| Propranolol Hcl Er | None | 22 | $1,221 | $56 |
| Primidone | None | 27 | $1,208 | $45 |
| Trospium Chloride | None | 18 | $1,165 | $65 |
| Mirtazapine | None | 35 | $1,101 | $31 |
| Duloxetine | None | 45 | $1,037 | $23 |
| Donepezil | None | 53 | $846 | $16 |
| Pregabalin | None | 11 | $687 | $62 |
| Quetiapine | None | 28 | $656 | $23 |
| Trazodone | None | 48 | $616 | $13 |
| Clonazepam | None | 38 | $613 | $16 |
| Bupropion | None | 14 | $577 | $41 |
| Baclofen | None | 16 | $529 | $33 |
| Ropinirole | None | 17 | $499 | $29 |
| Bupropion Xl | None | 16 | $495 | $31 |
| Trihexyphenidyl | None | 21 | $405 | $19 |
| Sertraline | None | 45 | $403 | $9 |
| Gabapentin | None | 16 | $328 | $20 |
| Propranolol | None | 14 | $264 | $19 |
| Hydroxyzine | None | 12 | $24 | $2 |
Year by year
| 2024 | 1,288 | 172 | None | None | $457,441 |
| 2023 | 1,812 | 228 | None | None | $658,596 |
| 2022 | 2,479 | 291 | None | 16% | $867,748 |
| 2021 | 1,948 | 270 | 1% (18) | 16% | $663,282 |
| 2020 | 1,363 | 128 | 2% (29) | 24% | $501,003 |
| 2019 | 1,218 | 95 | 2% (18) | None | $516,342 |
| 2018 | 1,259 | 95 | 3% (42) | 29% | $600,759 |
| 2017 | 1,051 | 86 | 2% (22) | 21% | $223,524 |
| 2016 | 806 | 68 | None | 17% | $156,709 |
| 2015 | 784 | 68 | None | 20% | $167,588 |
| 2014 | 559 | 66 | None | None | $75,661 |
| 2013 | 521 | 85 | None | 12% | $58,091 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Rytary | Parkinson's | 161 | $360,028 | $2,236 |
| Myrbetriq | None | 52 | $45,811 | $881 |
| Inbrija | None | 14 | $35,372 | $2,527 |
| Neupro | None | 33 | $33,525 | $1,016 |
| Carbidopa-Levodopa | None | 346 | $22,779 | $66 |
| Carbidopa-Levodopa Er | None | 90 | $17,300 | $192 |
| Carbidopa | None | 29 | $13,281 | $458 |
| Rivastigmine | None | 22 | $7,064 | $321 |
| Midodrine | None | 31 | $5,520 | $178 |
| Amantadine | None | 67 | $5,315 | $79 |
| Quetiapine | None | 42 | $5,198 | $124 |
| Primidone | None | 44 | $2,856 | $65 |
| Celecoxib | None | 40 | $2,413 | $60 |
| Duloxetine | None | 66 | $2,121 | $32 |
| Trospium Chloride | None | 27 | $2,029 | $75 |
| Mirtazapine | None | 42 | $1,962 | $47 |
| Clonazepam | None | 65 | $1,758 | $27 |
| Donepezil | None | 73 | $1,697 | $23 |
| Bupropion Xl | None | 36 | $1,686 | $47 |
| Propranolol Hcl Er | None | 39 | $1,424 | $37 |
| Pregabalin | None | 21 | $1,422 | $68 |
| Trazodone | None | 56 | $1,400 | $25 |
| Baclofen | None | 25 | $1,232 | $49 |
| Gabapentin | None | 24 | $1,157 | $48 |
| Glycopyrrolate | None | 21 | $922 | $44 |
| Sertraline | None | 66 | $838 | $13 |
| Escitalopram | None | 19 | $710 | $37 |
| Pramipexole Dihydrochloride | None | 14 | $619 | $44 |
| Trihexyphenidyl | None | 24 | $599 | $25 |
| Propranolol | None | 11 | $578 | $53 |
| Dextroamphetamine-Amphetamine | None | 11 | $510 | $46 |
| Bupropion | None | 13 | $203 | $16 |
| Naproxen | None | 11 | $58 | $5 |
2022: 38 drugs
| Rytary | Parkinson's | 227 | $420,524 | $1,853 |
| Ingrezza | None | 15 | $111,291 | $7,419 |
| Myrbetriq | None | 81 | $49,776 | $615 |
| Carbidopa-Levodopa | None | 480 | $43,527 | $91 |
| Carbidopa-Levodopa Er | None | 166 | $25,835 | $156 |
| Neupro | None | 22 | $24,525 | $1,115 |
| Carbidopa | None | 45 | $19,557 | $435 |
| Midodrine | None | 48 | $9,093 | $189 |
| Rivastigmine | None | 38 | $8,210 | $216 |
| Duloxetine | None | 99 | $6,961 | $70 |
| Quetiapine | None | 63 | $6,146 | $98 |
| Amantadine | None | 66 | $5,437 | $82 |
| Propranolol Hcl Er | None | 57 | $3,090 | $54 |
| Ropinirole Er | None | 28 | $2,132 | $76 |
| Glycopyrrolate | None | 34 | $2,097 | $62 |
| Mirtazapine | None | 65 | $2,088 | $32 |
| Baclofen | None | 42 | $1,955 | $47 |
| Gabapentin | None | 65 | $1,838 | $28 |
| Donepezil | None | 99 | $1,781 | $18 |
| Clonazepam | None | 99 | $1,593 | $16 |
| Trazodone | None | 74 | $1,565 | $21 |
| Trospium Chloride | None | 18 | $1,507 | $84 |
| Primidone | None | 35 | $1,304 | $37 |
| Fludrocortisone Acetate | None | 20 | $959 | $48 |
| Bupropion Xl | None | 34 | $953 | $28 |
| Trihexyphenidyl | None | 40 | $925 | $23 |
| Ropinirole | None | 19 | $887 | $47 |
| Propranolol | None | 23 | $837 | $36 |
| Pramipexole Dihydrochloride | None | 20 | $780 | $39 |
| Pregabalin | None | 18 | $679 | $38 |
| Pyridostigmine | None | 13 | $580 | $45 |
| Celecoxib | None | 14 | $469 | $33 |
| Sertraline | None | 49 | $446 | $9 |
| Escitalopram | None | 24 | $441 | $18 |
| Ondansetron | None | 13 | $305 | $23 |
| Bupropion | None | 18 | $222 | $12 |
| Imipramine | None | 12 | $131 | $11 |
| Lorazepam | None | 11 | $82 | $7 |
2021: 34 drugs
| Rytary | Parkinson's | 181 | $348,388 | $1,925 |
| Myrbetriq | None | 49 | $32,020 | $653 |
| Neupro | None | 23 | $27,519 | $1,196 |
| Carbidopa-Levodopa | None | 287 | $26,795 | $93 |
| Carbidopa | None | 63 | $20,728 | $329 |
| Carbidopa-Levodopa Er | None | 95 | $13,192 | $139 |
| Rivastigmine | None | 32 | $12,309 | $385 |
| Duloxetine | None | 108 | $5,711 | $53 |
| Baclofen | None | 61 | $4,438 | $73 |
| Propranolol Hcl Er | None | 55 | $3,901 | $71 |
| Amantadine | None | 35 | $3,666 | $105 |
| Mirtazapine | None | 95 | $3,449 | $36 |
| Midodrine | None | 30 | $2,994 | $100 |
| Quetiapine | None | 84 | $2,457 | $29 |
| Venlafaxine Hcl Er | None | 19 | $1,858 | $98 |
| Donepezil | None | 76 | $1,566 | $21 |
| Glycopyrrolate | None | 29 | $1,503 | $52 |
| Pyridostigmine | None | 17 | $1,273 | $75 |
| Pregabalin | None | 17 | $1,250 | $74 |
| Celecoxib | None | 24 | $1,185 | $49 |
| Clonazepam | None | 65 | $1,129 | $17 |
| Solifenacin | None | 15 | $1,084 | $72 |
| Propranolol | None | 24 | $848 | $35 |
| Pramipexole Dihydrochloride | None | 18 | $810 | $45 |
| Gabapentin | None | 27 | $809 | $30 |
| Trazodone | None | 80 | $745 | $9 |
| Bupropion Xl | None | 11 | $410 | $37 |
| Methylphenidate | None | 11 | $316 | $29 |
| Diclofenac | None | 15 | $299 | $20 |
| Bupropion | None | 19 | $294 | $15 |
| Oxycodone-Acetaminophen | None | 11 | $274 | $25 |
| Trihexyphenidyl | None | 11 | $223 | $20 |
| Sertraline | None | 16 | $188 | $12 |
| Escitalopram | None | 23 | $163 | $7 |
2020: 29 drugs
| Rytary | Parkinson's | 201 | $280,594 | $1,396 |
| Neupro | None | 24 | $26,048 | $1,085 |
| Inbrija | None | 13 | $24,862 | $1,912 |
| Myrbetriq | None | 31 | $24,660 | $795 |
| Nuedexta | None | 19 | $24,366 | $1,282 |
| Carbidopa | None | 22 | $15,301 | $695 |
| Rivastigmine | None | 29 | $13,677 | $472 |
| Carbidopa-Levodopa | None | 168 | $10,752 | $64 |
| Duloxetine | None | 99 | $7,663 | $77 |
| Entacapone | None | 20 | $5,616 | $281 |
| Carbidopa-Levodopa Er | None | 39 | $4,873 | $125 |
| Baclofen | None | 40 | $3,247 | $81 |
| Midodrine | None | 23 | $2,737 | $119 |
| Amantadine | None | 20 | $2,144 | $107 |
| Quetiapine | None | 50 | $1,919 | $38 |
| Donepezil | None | 65 | $1,440 | $22 |
| Venlafaxine Hcl Er | None | 22 | $1,316 | $60 |
| Galantamine Er | None | 13 | $1,068 | $82 |
| Propranolol Hcl Er | None | 20 | $969 | $48 |
| Methylphenidate | None | 20 | $859 | $43 |
| Gabapentin | None | 35 | $833 | $24 |
| Ropinirole | None | 11 | $797 | $72 |
| Trazodone | None | 60 | $744 | $12 |
| Mirtazapine | None | 27 | $730 | $27 |
| Glycopyrrolate | None | 22 | $698 | $32 |
| Pramipexole Dihydrochloride | None | 19 | $691 | $36 |
| Clonazepam | None | 62 | $502 | $8 |
| Escitalopram | None | 16 | $207 | $13 |
| Sertraline | None | 13 | $147 | $11 |
2019: 28 drugs
| Rytary | Parkinson's | 165 | $228,507 | $1,385 |
| Neupro | None | 17 | $19,208 | $1,130 |
| Rasagiline Mesylate | None | 18 | $18,123 | $1,007 |
| Nuedexta | None | 13 | $15,490 | $1,192 |
| Myrbetriq | None | 22 | $14,968 | $680 |
| Linzess | None | 21 | $13,156 | $626 |
| Carbidopa-Levodopa | None | 144 | $10,921 | $76 |
| Duloxetine | None | 107 | $10,716 | $100 |
| Rivastigmine | None | 17 | $9,609 | $565 |
| Entacapone | None | 24 | $7,406 | $309 |
| Carbidopa-Levodopa Er | None | 52 | $5,956 | $115 |
| Carbidopa | None | 14 | $5,909 | $422 |
| Midodrine | None | 30 | $3,169 | $106 |
| Amantadine | None | 29 | $3,137 | $108 |
| Quetiapine | None | 32 | $1,808 | $56 |
| Donepezil | None | 68 | $1,734 | $25 |
| Venlafaxine Hcl Er | None | 36 | $1,099 | $31 |
| Pyridostigmine | None | 14 | $873 | $62 |
| Methylphenidate | None | 16 | $873 | $55 |
| Glycopyrrolate | None | 12 | $847 | $71 |
| Gabapentin | None | 24 | $778 | $32 |
| Escitalopram | None | 11 | $765 | $70 |
| Baclofen | None | 18 | $718 | $40 |
| Pramipexole Dihydrochloride | None | 20 | $584 | $29 |
| Trazodone | None | 36 | $484 | $13 |
| Mirtazapine | None | 27 | $456 | $17 |
| Clonazepam | None | 48 | $397 | $8 |
| Clozapine | None | 27 | $116 | $4 |
2018: 29 drugs
| Northera | None | 12 | $223,265 | $18,605 |
| Rytary | Parkinson's | 157 | $175,070 | $1,115 |
| Neupro | None | 36 | $39,472 | $1,096 |
| Rasagiline Mesylate | None | 28 | $22,689 | $810 |
| Carbidopa | None | 20 | $15,841 | $792 |
| Myrbetriq | None | 18 | $12,439 | $691 |
| Lyrica | None | 11 | $10,665 | $970 |
| Entacapone | None | 26 | $10,276 | $395 |
| Linzess | None | 23 | $10,073 | $438 |
| Duloxetine | None | 101 | $9,293 | $92 |
| Carbidopa-Levodopa | None | 107 | $8,435 | $79 |
| Rivastigmine | None | 23 | $8,200 | $357 |
| Oxycontin | None | 18 | $6,087 | $338 |
| Carbidopa-Levodopa Er | None | 70 | $5,817 | $83 |
| Carbidopa-Levodopa-Entacapone | None | 18 | $4,552 | $253 |
| Midodrine | None | 30 | $3,917 | $131 |
| Amantadine | None | 35 | $3,185 | $91 |
| Donepezil | None | 72 | $3,002 | $42 |
| Pyridostigmine | None | 15 | $1,402 | $93 |
| Quetiapine | None | 30 | $1,328 | $44 |
| Glycopyrrolate | None | 30 | $1,230 | $41 |
| Trospium Chloride | None | 13 | $1,205 | $93 |
| Venlafaxine Hcl Er | None | 44 | $685 | $16 |
| Gabapentin | None | 31 | $602 | $19 |
| Pramipexole Dihydrochloride | None | 28 | $440 | $16 |
| Clonazepam | None | 28 | $353 | $13 |
| Trazodone | None | 18 | $310 | $17 |
| Mirtazapine | None | 21 | $305 | $15 |
| Omeprazole | None | 13 | $254 | $20 |
2017: 24 drugs
| Rytary | Parkinson's | 102 | $80,697 | $791 |
| Carbidopa | None | 30 | $18,493 | $616 |
| Entacapone | None | 19 | $12,821 | $675 |
| Duloxetine | None | 105 | $12,352 | $118 |
| Myrbetriq | None | 18 | $8,040 | $447 |
| Carbidopa-Levodopa | None | 91 | $7,763 | $85 |
| Carbidopa-Levodopa-Entacapone | None | 14 | $6,448 | $461 |
| Amantadine | None | 57 | $5,492 | $96 |
| Midodrine | None | 48 | $5,490 | $114 |
| Carbidopa-Levodopa Er | None | 51 | $3,817 | $75 |
| Rivastigmine | None | 14 | $2,777 | $198 |
| Donepezil | None | 38 | $1,978 | $52 |
| Etodolac | None | 18 | $1,238 | $69 |
| Gabapentin | None | 36 | $578 | $16 |
| Fludrocortisone Acetate | None | 16 | $499 | $31 |
| Venlafaxine Hcl Er | None | 41 | $457 | $11 |
| Mirtazapine | None | 42 | $454 | $11 |
| Quetiapine | None | 16 | $442 | $28 |
| Trazodone | None | 16 | $310 | $19 |
| Propranolol | None | 11 | $251 | $23 |
| Polyethylene Glycol 3350 | None | 15 | $237 | $16 |
| Pramipexole Dihydrochloride | None | 28 | $209 | $7 |
| Meloxicam | None | 13 | $118 | $9 |
| Baclofen | None | 12 | $104 | $9 |
2016: 25 drugs
| Rytary | Parkinson's | 39 | $43,211 | $1,108 |
| Carbidopa | None | 20 | $20,417 | $1,021 |
| Entacapone | None | 13 | $9,373 | $721 |
| Myrbetriq | None | 11 | $7,376 | $671 |
| Carbidopa-Levodopa | None | 93 | $7,226 | $78 |
| Amantadine | None | 39 | $6,173 | $158 |
| Duloxetine | None | 74 | $5,506 | $74 |
| Rivastigmine | None | 16 | $5,213 | $326 |
| Carbidopa-Levodopa-Entacapone | None | 11 | $4,496 | $409 |
| Carbidopa-Levodopa Er | None | 43 | $3,408 | $79 |
| Midodrine | None | 20 | $3,400 | $170 |
| Ropinirole Er | None | 11 | $1,587 | $144 |
| Fludrocortisone Acetate | None | 16 | $1,460 | $91 |
| Donepezil | None | 53 | $948 | $18 |
| Gabapentin | None | 39 | $946 | $24 |
| Selegiline | None | 14 | $875 | $63 |
| Pramipexole Dihydrochloride | None | 25 | $838 | $34 |
| Rivastigmine | None | 15 | $776 | $52 |
| Polyethylene Glycol 3350 | None | 15 | $405 | $27 |
| Venlafaxine Hcl Er | None | 13 | $397 | $31 |
| Clonazepam | None | 27 | $272 | $10 |
| Mirtazapine | None | 18 | $219 | $12 |
| Quetiapine | None | 12 | $211 | $18 |
| Propranolol | None | 13 | $91 | $7 |
| Ranitidine | None | 11 | $35 | $3 |
2015: 21 drugs
| Carbidopa | None | 13 | $24,290 | $1,868 |
| Rytary | Parkinson's | 26 | $21,828 | $840 |
| Myrbetriq | None | 23 | $14,378 | $625 |
| Carbidopa-Levodopa-Entacapone | None | 13 | $7,891 | $607 |
| Amantadine | None | 43 | $7,789 | $181 |
| Carbidopa-Levodopa Er | None | 86 | $7,642 | $89 |
| Lyrica | None | 20 | $7,558 | $378 |
| Carbidopa-Levodopa | None | 75 | $5,485 | $73 |
| Duloxetine | None | 33 | $5,382 | $163 |
| Midodrine | None | 24 | $4,953 | $206 |
| Ropinirole Er | None | 13 | $2,482 | $191 |
| Selegiline | None | 17 | $987 | $58 |
| Donepezil | None | 39 | $856 | $22 |
| Pramipexole Dihydrochloride | None | 23 | $710 | $31 |
| Gabapentin | None | 27 | $351 | $13 |
| Quetiapine | None | 31 | $335 | $11 |
| Clonazepam | None | 49 | $232 | $5 |
| Mirtazapine | None | 14 | $214 | $15 |
| Venlafaxine Hcl Er | None | 12 | $187 | $16 |
| Escitalopram | None | 12 | $149 | $12 |
| Citalopram Hbr | None | 11 | $55 | $5 |
2014: 15 drugs
| Carbidopa-Levodopa | 72 | $7,576 | $105 |
| Duloxetine | 17 | $5,406 | $318 |
| Carbidopa-Levodopa Er | 63 | $4,757 | $76 |
| Amantadine | 28 | $4,133 | $148 |
| Galantamine Hbr | 12 | $1,812 | $151 |
| Midodrine | 19 | $1,411 | $74 |
| Fludrocortisone Acetate | 14 | $1,171 | $84 |
| Donepezil | 36 | $607 | $17 |
| Quetiapine | 31 | $542 | $17 |
| Gabapentin | 17 | $457 | $27 |
| Clonazepam | 29 | $195 | $7 |
| Baclofen | 13 | $188 | $14 |
| Trazodone | 13 | $181 | $14 |
| Mirtazapine | 16 | $180 | $11 |
| Citalopram Hbr | 16 | $123 | $8 |
2013: 10 drugs
| Carbidopa-Levodopa | 74 | $6,467 | $87 |
| Carbidopa-Levodopa Er | 72 | $5,612 | $78 |
| Pramipexole Dihydrochloride | 29 | $3,102 | $107 |
| Donepezil | 80 | $3,012 | $38 |
| Amantadine | 11 | $2,180 | $198 |
| Fludrocortisone Acetate | 17 | $887 | $52 |
| Quetiapine | 15 | $423 | $28 |
| Baclofen | 30 | $314 | $10 |
| Clonazepam | 41 | $290 | $7 |
| Citalopram Hbr | 19 | $198 | $10 |
Money from drug and device companies
$30 in 2025
| 2025 | 1 | 1 | None | $30 |
| 2022 | 1 | 1 | None | $107 |
| 2020 | 1 | 1 | None | $13 |
| 2019 | 4 | 8 | None | $454 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Botox | $30 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-10-09 | Botox | $30 |
See earlier years (2022, 2020, 2019)
2022: $107
| Boston Scientific | General - Dbs | $107 | 1 payment
|
2020: $13
| Neurocrine Biosciences | Ingrezza | $13 | 1 payment
|
2019: $454
| Medtronic USA | Activa | $391 | 5 payments
|
| Allergan | Botox | $24 | 1 payment
|
| AbbVie | Duopa | $20 | 1 payment
|
| Boston Scientific | General Dbs | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1427218304
- Licence
- CA A115851, NY 252476California A115851: Current · expires 2028-06-30
- Trained
- Js Weill Medical College, Cornell University, 2007
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-13
- NPI last updated
- 2023-11-06
- NPI record certified
- 2023-11-06
This is when the NPI record was last certified, not a medical board exam.